Edition:
India

Steadymed Ltd (STDY.OQ)

STDY.OQ on NASDAQ Stock Exchange Global Market

3.30USD
15 Dec 2017
Change (% chg)

$-0.05 (-1.49%)
Prev Close
$3.35
Open
$3.35
Day's High
$3.35
Day's Low
$3.17
Volume
41,555
Avg. Vol
14,325
52-wk High
$9.65
52-wk Low
$2.55

Chart for

About

SteadyMed Ltd. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of various therapeutic product candidates. Its primary focus is to obtain approval in the United States for the sale of Trevyent for the treatment of pulmonary arterial hypertension (PAH). It is also developing... (more)

Overall

Beta: --
Market Cap(Mil.): $84.98
Shares Outstanding(Mil.): 26.56
Dividend: --
Yield (%): --

Financials

BRIEF-SteadyMed Announces FDA Agreed Pathway To Trevyent NDA Resubmission

* STEADYMED ANNOUNCES FDA AGREED PATHWAY TO TREVYENT NDA RESUBMISSION

08 Dec 2017

BRIEF-STEADYMED RECEIVES FAVORABLE RULING FROM U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT

* ‍COURT OF APPEALS AFFIRMED A MARCH 31 RULING BY PATENT TRIAL & APPEAL BOARD INVALIDATING U.S. PATENT NO 8,497,393 OWNED BY UNITED THERAPEUTICS​

14 Nov 2017

BRIEF-Steadymed reports Q3 earnings per share $0.35

* Steadymed reports third quarter 2017 financial results and provides corporate update

13 Nov 2017

BRIEF-Steadymed receives notice of allowance for European patent

* Steadymed receives notice of allowance for its European patent relating to enhanced reduction of infusion-site pain Source text for Eikon: Further company coverage:

12 Oct 2017

BRIEF-SteadyMed submits type A meeting request package to FDA

* SteadyMed Ltd - ‍type A meeting is being requested in response to FDA's August 28, refusal to file letter relating to co's NDA for Trevyent​ Source text for Eikon: Further company coverage:

28 Sep 2017

BRIEF-SteadyMed receives refusal to file letter from FDA for Trevyent new drug application

* SteadyMed Ltd - FDA determined that application is not sufficiently complete to permit a substantive review

31 Aug 2017

BRIEF-Steadymed Ltd reports Q2 loss per share of $0.33

* Steadymed reports second quarter 2017 financial results and provides corporate update

11 Aug 2017

Earnings vs. Estimates